Geode Capital Management LLC Lowers Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Geode Capital Management LLC reduced its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 1.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,447,512 shares of the company’s stock after selling 68,026 shares during the quarter. Geode Capital Management LLC’s holdings in X4 Pharmaceuticals were worth $2,308,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in XFOR. State Street Corp boosted its position in shares of X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after acquiring an additional 189,105 shares during the last quarter. Ensign Peak Advisors Inc raised its position in shares of X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after buying an additional 111,032 shares during the period. Point72 Asset Management L.P. boosted its holdings in X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after acquiring an additional 81,968 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $340,000. Finally, K2 Principal Fund L.P. acquired a new position in shares of X4 Pharmaceuticals in the 2nd quarter valued at about $284,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ XFOR opened at $0.70 on Wednesday. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average price of $0.54 and a two-hundred day moving average price of $0.63. The firm has a market cap of $119.72 million, a PE ratio of -7.80 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60.

Wall Street Analyst Weigh In

XFOR has been the topic of several research reports. HC Wainwright cut their price target on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.